1. Home
  2. NIO vs RGEN Comparison

NIO vs RGEN Comparison

Compare NIO & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NIO Inc. American depositary shares each  representing one ordinary share

NIO

NIO Inc. American depositary shares each representing one ordinary share

HOLD

Current Price

$5.01

Market Cap

12.4B

ML Signal

HOLD

Logo Repligen Corporation

RGEN

Repligen Corporation

HOLD

Current Price

$162.51

Market Cap

8.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NIO
RGEN
Founded
2014
1981
Country
China
United States
Employees
N/A
N/A
Industry
Auto Manufacturing
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.4B
8.2B
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
NIO
RGEN
Price
$5.01
$162.51
Analyst Decision
Buy
Buy
Analyst Count
9
10
Target Price
$6.73
$174.90
AVG Volume (30 Days)
45.1M
701.7K
Earning Date
11-25-2025
10-28-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.03
Revenue
$10,189,444,895.00
$707,890,000.00
Revenue This Year
$35.91
$17.84
Revenue Next Year
$46.42
$12.57
P/E Ratio
N/A
$5,259.20
Revenue Growth
14.90
11.74
52 Week Low
$3.02
$102.97
52 Week High
$8.02
$182.52

Technical Indicators

Market Signals
Indicator
NIO
RGEN
Relative Strength Index (RSI) 36.43 54.15
Support Level $4.88 $156.01
Resistance Level $5.06 $165.02
Average True Range (ATR) 0.16 4.65
MACD 0.05 -1.07
Stochastic Oscillator 52.15 43.33

Price Performance

Historical Comparison
NIO
RGEN

About NIO NIO Inc. American depositary shares each representing one ordinary share

Nio is a leading electric vehicle maker, targeting the premium segment. Founded in November 2014, Nio designs, develops, jointly manufactures, and sells premium smart electric vehicles. The company differentiates itself through continuous technological breakthroughs and innovations such as battery swapping and autonomous driving technologies. Nio launched its first model, its ES8 seven-seater electric SUV, in December 2017, and began deliveries in June 2018. Its current model portfolio includes midsize to large sedans and SUVs. It sold around 222,000 EVs in 2024, accounting for about 2% of the China passenger new energy vehicle market.

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Share on Social Networks: